SCHEMBL18385809

SCHEMBL18385809

COc1cccc(=O)n(-c2ccc(OC)cc2)cc(-c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
PKM P14618 1/20 0.49
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
KMT2A Q03164 2/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
BRD4 O60885 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
LMNA P02545 1/20 0.46
OXTR P30559 1/20 0.46
BACE1 P56817 1/20 0.45
ALDH1A1 P00352 2/20 0.45
HTT P42858 1/20 0.45
ALDH1A3 P47895 1/20 0.45
NPBWR1 P48145 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10059808 0.94 MAPT (0.51) MAPTPKMNPC1RAB9AKMT2A
SCHEMBL10079104 0.89 KDM4E (0.53) MAPTPKMNPC1RAB9AKMT2A
SCHEMBL16474688 0.88 MEN1 (0.47) MAPTPKMKMT2AGAAHPGD
SCHEMBL18381976 0.87 MAPT (0.45) MAPTPKMNPC1RAB9AKMT2A
SCHEMBL16474678 0.85 BRD4 (0.58) MAPTKMT2AGAAHPGDBRD4
SCHEMBL10079704 0.84 BRD4 (0.65) MAPTHPGDBRD4SMN1; SMN2KDM4E
SCHEMBL16474692 0.84 BRD4 (0.56) MAPTPKMNPC1RAB9AKMT2A
SCHEMBL16474699 0.81 BRD4 (0.50) MAPTRAB9AKMT2ABRD4MEN1
SCHEMBL10059918 0.81 HRH3 (0.53) NPC1RAB9AKMT2AHPGDKDM4E
SCHEMBL16474686 0.81 MAPT (0.52) MAPTRAB9AKMT2AGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170014401-A1 NUCLEAR RECEPTOR BINDING AGENTS GTX, INC. 2017-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170014401-A1 NUCLEAR RECEPTOR BINDING AGENTS ESRRB, ESRRG, ESRRA MAPT 4533/4885PKM 3307/4885NPC1 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.